We are pleased to announce that GeneFluidics has been selected as one of five finalists for the Antimicrobial Resistance Diagnostic (AMR) Challenge Step 2 by National Institute of Health (NIH). The main purpose of the Antimicrobial Resistance Rapid Challenge is to incentivize the development of in vitro diagnostic tests that would be of significant clinical … Continue reading GeneFluidics selected as one of five finalists for Antimicrobial Resistance Diagnostic (AMR) Challenge Step 2